Monitor for announcement of final agreement terms, including upfront payments, milestones, and financing method. The addition of two clinical-stage oncology assets meaningfully expands Kairos’s pipeline in a high-value, scientifically validated therapeutic area. Positive preclinical profiles suggest potential for accelerated development given Kairos’s existing clinical infrastructure.
Price Chart
Executive Summary
Kairos Pharma (KAPA) announced a letter of intent to acquire worldwide rights to two clinical-stage oncology assets, CL-273 and CL-741, from privately held Celyn Therapeutics. The assets target non-small cell lung cancer (NSCLC) and are positioned to address resistance mechanisms in EGFR-mutant tumors through dual pathway inhibition.
Key Facts
- Kairos Pharma entered into a term sheet to acquire worldwide rights to CL-273 (pre-IND pan-EGFR inhibitor) and CL-741 (Phase 1-ready c-MET inhibitor) from Celyn Therapeutics.
- Both assets target non-small cell lung cancer (NSCLC), with a focus on overcoming resistance in EGFR-mutant tumors via dual EGFR and MET inhibition.
- CL-273 is pre-IND with first-in-human trials projected for 2026; CL-741 is Phase 1-ready.
- The acquisition is not yet finalized and remains subject to negotiation, regulatory, and shareholder approvals.
- Celyn Therapeutics is backed by OrbiMed and Torrey Pines Investment.
Financial Impact
No financial terms disclosed. Transaction value, payment structure, and dilution impact are unknown at this stage.
Risk Factors
- Transaction may not close due to failure to agree on final terms, regulatory hurdles, or lack of shareholder approval.
- Development timelines may be delayed; clinical trials may fail to demonstrate safety or efficacy.
- Future financing (equity or debt) could dilute shareholders or increase leverage.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-008116 |
| Exhibit: ex99-1.htm | 0001493152-26-008116 |
| Document: 0001493152-26-008116-index-headers.html | 0001493152-26-008116 |
| Document: 0001493152-26-008116-index.html | 0001493152-26-008116 |
| Document: 0001493152-26-008116.txt | 0001493152-26-008116 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 8-K | $1.15 $0.8287 | ▼ −27.94% | ▼ −27.80% | $0.5300 (−53.91%) |
Jul 22, 2026 13w ago | 8-K | $0.3127 $0.2990 | ▼ −4.38% | ▼ −1.98% | $0.5300 (+69.49%) |
Jul 15, 2026 14w ago | 8-K | $0.3180 $0.3127 | ▼ −1.67% | ▼ −0.69% | $0.5300 (+66.67%) |
Jun 4, 2026 20w ago | 8-K | $0.4660 $0.4580 | ▼ −1.72% | ▲ +0.84% | $0.5300 (+13.73%) |
May 26, 2026 21w ago | DEFA14A | $0.5170 $0.4620 | ▼ −10.64% | ▼ −11.11% | $0.5300 (+2.51%) |
Feb 26, 2026 34w ago | 8-K | $0.5520 $0.6560 | ▲ +18.84% | ▲ +19.97% | $0.5300 (−3.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers